

Supportive Place for Observation and Treatment (SPOT)



Photo Credit: AthenaHealth

Jessie M. Gaeta, MD

Chief Medical Officer, Boston Health Care for the Homeless Program

Assistant Professor, Boston University School of Medicine


BHCHP's Main Practice



OBJECTIVE

Implement a harm reduction program within a health care setting, in order to:

1. Prevent fatal overdose
2. More effectively connect highest-risk individuals with treatment
3. Tackle stigma



PROGRAM CONCEPT



Services Offered

- Medical monitoring during sedation
- Treatment of overdose (oxygen, IV fluids, naloxone)
- Counseling about safer injection techniques
- Connection to primary care, behavioral health services, and addictions treatment
- Naloxone rescue kit distribution

Staffing Model

- Registered nurse specializing in addiction
- Harm reduction specialist builds relationships and links people to treatment
- Rapid response clinician (MD/NP/PA) available for emergency



CONSUMER INVOLVEMENT

- Participated in weekly planning meetings
- Perspectives sought in survey conducted at syringe exchange program before opening
- Interviewed harm reduction applicants
- Patient experience survey



SUPPORTIVE PLACE FOR OBSERVATION AND TREATMENT



SPOT RESEARCH ROADMAP

1. Environment

1A. Consumer willingness
to use harm reduction
program

✓ Before opening SPOT, 91% of injection drug users reported willingness to use harm reduction programs, and those most likely to use such spaces were among those at highest risk of overdose.¹

1B. Community
perceptions of SPOT

✓ Significant increases in community knowledge about drugs, favorable attitudes towards harm reduction, and favorable attitudes towards our intervention following the opening of SPOT.²

1C. Evaluating public
order, pre- and post-SPOT
(first 12 weeks)

✓ SPOT was associated with a significant decrease in observed over-sedated individuals; injection-drug related public order (e.g., publicly discarded syringes, injection-related litter) did not worsen.³



1. León, C., Cardoso, L., Mackin, S., Bock, B., & Gaeta, J. M. (2017). The willingness of people who inject drugs in Boston to use a supervised injection facility. *Substance Abuse*, 1-7.

2. Cardoso, L. J., León, C., Bock, B., & Gaeta, J. Changes in community attitudes about substance use and harm reduction approaches after the opening of a new medical monitoring facility (in development).

3. León, C., Cardoso, L. J., Johnston, S., Mackin, S., Bock, B., & Gaeta, J. M. (2018). Changes in public order after the opening of an overdose monitoring facility for people who inject drugs. *International Journal of Drug Policy*, 53, 90-95.

SPOT RESEARCH ROADMAP

1. Environment

✓ 1A. Consumer willingness to use harm reduction program

✓ 1B. Community perceptions of SPOT

✓ 1C. Evaluating public order, pre- and post-SPOT (first 12 weeks)

2. Participant Population

✓ 2A. Internal dashboard / population profile

SPOT Stats, April 2016-2018

7,139	Total visits
666	De-duplicated visitors
34%	Participants who identify as women
47	Naloxone administrations
488	Oxygen administrations
987	ED avoidances (nurse-reported)
22%	Direct referrals to addiction treatment
20%	Direct connections to medical/BH care

WHAT WE'RE LEARNING

- Cohort using program is extremely high risk
- Nature of relationship with participants is quite different than in other clinical settings
- Substance use is layered with “cocktail”
 - Opioid
 - Benzodiazepine
 - Clonidine
 - Gabapentin
 - Promethazine
- **Participants reluctant to seek health care services elsewhere because of stigma**



SPOT RESEARCH ROADMAP

1. Environment

✓ 1A. Consumer willingness to use harm reduction program

✓ 1B. Community perceptions of SPOT

✓ 1C. Evaluating public order, pre- and post-SPOT (first 12 weeks)

2. Participant Population

✓ 2A. Internal dashboard / population profile

2B. Polysubstance overdose syndrome (cluster analysis)

2C. Participant substance use patterns, acute & chronic health issues

POLYSUBSTANCE OVERDOSE SYNDROME

Vital signs monitoring in SPOT often shows bradycardia and hypotension, in addition to sedation and respiratory depression, thought to be a result of polysubstance use.



POLYSUBSTANCE OVERDOSE SYNDROME

Table 1. Characteristics of intoxication clusters

	Cluster A: Mild (N=81 episodes)	Cluster B: Moderate (N=136 episodes)	Cluster C: Severe (N=88 episodes)
Sedation level (0-6), mean (SD)	3.6 (0.8)	4.5 (0.6)	4.5 (0.5)
Sedation level ≥5, N (%)	2 (2.5)	70 (51.5)	41 (46.6)
Systolic blood pressure nadir (mm Hg), mean (SD)	113.5 (13.3)	94.5 (13.6)	89.2 (12.8)
Systolic blood pressure nadir <90mm Hg, N (%)	4 (4.9)	54 (39.7)	43 (48.9)
Pulse nadir (beats/min), mean (SD)	80.2 (18.0)	57.3 (11.1)	59.2 (11.9)
Pulse nadir <60 beats/min, N (%)	10 (12.4)	83 (61.0)	53 (60.2)
Respiratory rate nadir (breaths/min), mean (SD)	13.5 (1.9)	11.7 (0.9)	11.7 (0.8)
Respiratory rate <12 breaths/min, N (%)	3 (3.7)	18 (13.2)	14 (15.9)
Oxygen saturation nadir (%), mean (SD)	95.8 (2.2)	95.4 (1.5)	91.1 (1.7)
Oxygen saturation <95%, N (%)	21 (25.9)	41 (30.2)	88 (100)

Qualitative description of clusters:

- Cluster A: mild sedation with stable vital signs
- Cluster B: moderate sedation with non-hypoxic vital sign abnormalities
- Cluster C: moderate sedation with hypoxia and other vital sign abnormalities

POLYSUBSTANCE OVERDOSE SYNDROME

Table 2. Demographic and self-reported substance ingestion characteristics overall and by intoxication cluster

	Overall (N=305 episodes)	Cluster A: Mild (N=81 episodes)	Cluster B: Moderate (N=136 episodes)	P value (B vs A)	Cluster C: Severe (N=88 episodes)	P value (C vs A)
Demographics						
Age (years), mean (SD)	39.0 (9.4)	38.0 (10.0)	37.5 (8.8)	0.77	42.3 (9.0)	0.04
Female, N (%)	137 (44.9)	29 (35.8)	59 (43.4)	0.38	49 (55.7)	0.07
Substance ingestions						
Opioids, N (%)	219 (71.8)	66 (81.5)	96 (70.6)	0.10	57 (64.8)	0.02
Sedating medications, N (%)						
Benzodiazepines	172 (56.4)	29 (35.8)	83 (61.0)	0.001	60 (68.2)	<0.001
Clonidine	165 (54.1)	24 (29.6)	86 (63.2)	<0.001	55 (62.5)	0.002
Promethazine	114 (37.4)	16 (19.8)	64 (47.1)	<0.001	34 (38.6)	0.03
Gabapentin	112 (36.7)	16 (19.8)	61 (44.9)	<0.001	35 (39.8)	0.03
Any of above	193 (63.3)	34 (42.0)	92 (67.7)	0.001	67 (76.1)	<0.001
Stimulants, N (%)						
Cocaine/crack	18 (5.9)	8 (9.9)	6 (4.4)	0.15	4 (4.6)	0.20
Methamphetamine	5 (1.6)	2 (2.5)	2 (1.5)	0.60	1 (1.1)	0.52
Any of above	23 (7.5)	10 (12.4)	8 (5.9)	0.11	5 (5.7)	0.14
Cannabinoids, N (%)						
Marijuana	3 (1.0)	1 (1.2)	2 (1.5)	0.89	0 (0)	--
Synthetic cannabinoids	17 (5.6)	6 (7.4)	10 (7.4)	0.99	1 (1.1)	0.10
Any of above	20 (6.6)	7 (8.6)	12 (8.8)	0.97	1 (1.1)	0.07
Alcohol, N (%)	11 (3.6)	5 (6.2)	3 (2.2)	0.23	3 (3.4)	0.41

Qualitative summary: Cluster B and C patients were more likely to have ingested sedating medications. Cluster C patients were slightly older, marginally more likely to be female, less likely to have ingested opioids, and marginally less likely to have ingested cannabinoids.

POLYSUBSTANCE OVERDOSE SYNDROME

Table 3. Multivariable associations with intoxication cluster membership.

	Adjusted OR (95% CI) Cluster B vs A	Adjusted OR (95% CI) Cluster C vs A
Demographics		
Age, per 10 years	0.93 (0.64, 1.36)	1.54 (1.00, 2.35)
Female	1.44 (0.71, 2.92)	2.51 (1.03, 6.10)
Substance ingestions		
Opioids	0.65 (0.27, 1.61)	0.53 (0.23, 1.25)
Sedating medications	2.75 (1.40, 5.40)	3.38 (1.48, 7.70)
Stimulants	0.57 (0.22, 1.47)	0.64 (0.20, 2.02)
Cannabinoids	1.29 (0.41, 4.01)	0.24 (0.03, 2.10)
Alcohol	0.28 (0.06, 1.44)	0.37 (0.09, 1.54)

Qualitative summary: In multivariable models, ingestion of sedating medications was the strongest predictor of intoxication syndrome severity. Older age and female sex were associated with higher odds of severe (cluster C) intoxication syndromes.

SPOT RESEARCH CHALLENGES

- Not insignificant issues around gaining consent
 - Desire to maintain trusting relationships with participants
 - Participants' engagement in illicit behavior
 - Sedation and its impact on ability to give consent
- Need to prevent research from being viewed as encouraging participants to use again
- At SPOT, beginning data collection at unknown time point in symptom progression
- Difficult to follow participants over time given the instability in their lives

SPOT RESEARCH ROADMAP

1. Environment

✓ 1A. Consumer willingness to use harm reduction program

✓ 1B. Community perceptions of SPOT

✓ 1C. Evaluating public order, pre- and post-SPOT (first 12 weeks)

2. Participant Population

✓ 2A. Internal dashboard / population profile

2B. Polysubstance overdose syndrome (case series)

2C. Participant substance use patterns, acute & chronic health issues

3. Impact

3A. Impact of SPOT on OD rates & ED utilization

3B. Impact of SPOT on SUD treatment initiation & engagement

3C. Changes in SPOT user risk behavior over time (cohort study)

- Disproportionate effect of overdose deaths among homeless population
- Harm reduction services play a crucial and complementary role in SUD treatment continuum
- SPOT doesn't go far enough – unable to prevent fatal OD at point of injection

What do we see?



Image courtesy Boston Globe

With Thanks

SPOT Clinical Team

Led by Kate Orlin & Courtney Kenney

BHCHP Leadership

Barry Bock, CEO

James O'Connell, President

AHOPE

of Boston Public Health Commission

BHCHP's Institute for Research, Quality, and Policy in Homeless Health Care

Travis Baggett, Director of Research

Casey K. León, former Institute Director

Gabriel Wishik, MD

Melanie Racine, Project Manager

Lena Cardoso, Research Associate

Salem Johnston, Analyst

Contact:

Jessie M. Gaeta, MD

Chief Medical Officer, Boston Health Care for the Homeless Program

780 Albany St. Boston, MA 02118

Assistant Professor, Boston University School of Medicine

jgaeta@bhchp.org